NYSE · SI
Shoulder Innovations, Inc.
$20.44+$0.96 (+4.93%)
Shoulder Innovations, Inc.’s quoted price sits in the upper half of its reported 52-week range, 16.91% below the high.
Loading market information…
NASDAQ · OM · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Outset Medical, Inc.’s quoted price sits in the lower half of its reported 52-week range, 68.71% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Outset Medical, Inc.’s next earnings report is currently expected on Nov 4, 2026, with estimated earnings per share of -$0.64. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Outset Medical, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Outset Medical, Inc. is a medical technology firm that specializes in developing hemodialysis systems. The company's primary product is the Tablo Hemodialysis System, a compact console designed to deliver dialysis treatment in various environments, including hospitals and patients' homes. This innovative system boasts integrated water purification, on-demand production of dialysate, and advanced software complete with connectivity features. Founded in 2003, the company initially operated under the name Home Dialysis Plus, Ltd. before rebranding to Outset Medical, Inc. in January 2015. Its corporate headquarters are located in San Jose, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:09 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 7, 2025 | -$3.24-242.86% vs estimate | $29.75M+6.98% vs estimate |
|---|
| Q4 2024 | Feb 19, 2025 | -$5.55+10.49% vs estimate | $29.47M+3.49% vs estimate |
|---|
| Q3 2024 | Nov 6, 2024 | -$5.85-1,362.5% vs estimate | $28.67M+6.57% vs estimate |
|---|
THE ANALYST VIEW
11 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$20.44+$0.96 (+4.93%)
Shoulder Innovations, Inc.’s quoted price sits in the upper half of its reported 52-week range, 16.91% below the high.
$9.95-$0.04 (-0.4%)
Viemed Healthcare, Inc.’s quoted price sits in the upper half of its reported 52-week range, 21.09% below the high.
$2.68+$0.22 (+8.94%)
Owens & Minor, Inc.’s quoted price sits in the lower half of its reported 52-week range, 82.75% below the high.
$7.26+$0.01 (+0.14%)
Inogen, Inc.’s quoted price sits in the upper half of its reported 52-week range, 15.09% below the high.
$3.15+$0.03 (+0.8%)
Quanterix Corporation’s quoted price sits in the lower half of its reported 52-week range, 64.14% below the high.
$1.17-$0.08 (-6.02%)
Perspective Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 81.01% below the high.
$2.26-$0.03 (-1.31%)
Solana Company’s quoted price sits in the lower half of its reported 52-week range, 66.27% below the high.
$0.40-$0.01 (-1.34%)
Tenaya Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 74.46% below the high.
